PROM1 and cancer: The concept of recombinant T cells with specificity for killing the cancer cells, constitutes a possible potent therapeutic modality, such as the use of anti-CD133 CAR T-cells (4th generation) for CCA that express CD133, provided beneficial effect on the tumors, however, due to its possible toxicity, the use of this modality is still under study.